{"title":"功能状态增强FRAX®预测重症肌无力骨折:一项10年队列研究。","authors":"Shingo Konno, Takafumi Uchi, Hideo Kihara, Hideki Sugimoto","doi":"10.3390/jcm14093260","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background</b>: Patients with myasthenia gravis (MG) are susceptible to fractures due to glucocorticoid (GC) use and disease-related functional impairment affecting activities of daily living (ADL). The Fracture Risk Assessment Tool (FRAX<sup>®</sup>) estimates fracture probability but does not incorporate disease-specific functional status. We investigated whether combining FRAX<sup>®</sup> with the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale improves fracture risk stratification in MG patients. <b>Methods</b>: This single-center prospective cohort study followed 53 MG patients for 10 years (2012-2022) at Toho University Ohashi Medical Center, Japan. Patients were categorized into four groups based on baseline FRAX<sup>®</sup> probability (calculated with bone mineral density [BMD]) and MG-ADL scores using median splits: high FRAX<sup>®</sup>/high MG-ADL (HH), high FRAX<sup>®</sup>/low MG-ADL (HL), low FRAX<sup>®</sup>/high MG-ADL (LH), and low FRAX<sup>®</sup>/low MG-ADL (LL). The primary outcome was incident major osteoporotic fracture (MOF). <b>Results</b>: Over 10 years, nine MOFs occurred: seven in the HH group (43.8%), two in the HL group (16.7%), and none in the LH or LL groups. Fracture-free survival differed significantly among the groups (log-rank <i>p</i> < 0.001), with the HH group exhibiting the lowest survival rate. Baseline characteristics, including age, disease duration, MG severity scores, BMD, and FRAX<sup>®</sup> scores, differed significantly among groups. Specific MG-ADL items reflecting greater impairment (impairment of ability to arise from a chair, double vision, and ptosis) were significantly more pronounced in the HH group at baseline. <b>Conclusions</b>: Combining baseline FRAX<sup>®</sup> scores with the MG-ADL assessment effectively stratifies long-term MOF risk in patients with MG. Individuals with both high FRAX<sup>®</sup> and high MG-ADL represent a particularly high-risk subgroup. This dual-assessment approach may improve the identification of patients requiring targeted preventive interventions.</p>","PeriodicalId":15533,"journal":{"name":"Journal of Clinical Medicine","volume":"14 9","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12072394/pdf/","citationCount":"0","resultStr":"{\"title\":\"Functional Status Enhances the FRAX<sup>®</sup> Prediction of Fractures in Myasthenia Gravis: A 10-Year Cohort Study.\",\"authors\":\"Shingo Konno, Takafumi Uchi, Hideo Kihara, Hideki Sugimoto\",\"doi\":\"10.3390/jcm14093260\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background</b>: Patients with myasthenia gravis (MG) are susceptible to fractures due to glucocorticoid (GC) use and disease-related functional impairment affecting activities of daily living (ADL). The Fracture Risk Assessment Tool (FRAX<sup>®</sup>) estimates fracture probability but does not incorporate disease-specific functional status. We investigated whether combining FRAX<sup>®</sup> with the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale improves fracture risk stratification in MG patients. <b>Methods</b>: This single-center prospective cohort study followed 53 MG patients for 10 years (2012-2022) at Toho University Ohashi Medical Center, Japan. Patients were categorized into four groups based on baseline FRAX<sup>®</sup> probability (calculated with bone mineral density [BMD]) and MG-ADL scores using median splits: high FRAX<sup>®</sup>/high MG-ADL (HH), high FRAX<sup>®</sup>/low MG-ADL (HL), low FRAX<sup>®</sup>/high MG-ADL (LH), and low FRAX<sup>®</sup>/low MG-ADL (LL). The primary outcome was incident major osteoporotic fracture (MOF). <b>Results</b>: Over 10 years, nine MOFs occurred: seven in the HH group (43.8%), two in the HL group (16.7%), and none in the LH or LL groups. Fracture-free survival differed significantly among the groups (log-rank <i>p</i> < 0.001), with the HH group exhibiting the lowest survival rate. Baseline characteristics, including age, disease duration, MG severity scores, BMD, and FRAX<sup>®</sup> scores, differed significantly among groups. Specific MG-ADL items reflecting greater impairment (impairment of ability to arise from a chair, double vision, and ptosis) were significantly more pronounced in the HH group at baseline. <b>Conclusions</b>: Combining baseline FRAX<sup>®</sup> scores with the MG-ADL assessment effectively stratifies long-term MOF risk in patients with MG. Individuals with both high FRAX<sup>®</sup> and high MG-ADL represent a particularly high-risk subgroup. This dual-assessment approach may improve the identification of patients requiring targeted preventive interventions.</p>\",\"PeriodicalId\":15533,\"journal\":{\"name\":\"Journal of Clinical Medicine\",\"volume\":\"14 9\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12072394/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/jcm14093260\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jcm14093260","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Functional Status Enhances the FRAX® Prediction of Fractures in Myasthenia Gravis: A 10-Year Cohort Study.
Background: Patients with myasthenia gravis (MG) are susceptible to fractures due to glucocorticoid (GC) use and disease-related functional impairment affecting activities of daily living (ADL). The Fracture Risk Assessment Tool (FRAX®) estimates fracture probability but does not incorporate disease-specific functional status. We investigated whether combining FRAX® with the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale improves fracture risk stratification in MG patients. Methods: This single-center prospective cohort study followed 53 MG patients for 10 years (2012-2022) at Toho University Ohashi Medical Center, Japan. Patients were categorized into four groups based on baseline FRAX® probability (calculated with bone mineral density [BMD]) and MG-ADL scores using median splits: high FRAX®/high MG-ADL (HH), high FRAX®/low MG-ADL (HL), low FRAX®/high MG-ADL (LH), and low FRAX®/low MG-ADL (LL). The primary outcome was incident major osteoporotic fracture (MOF). Results: Over 10 years, nine MOFs occurred: seven in the HH group (43.8%), two in the HL group (16.7%), and none in the LH or LL groups. Fracture-free survival differed significantly among the groups (log-rank p < 0.001), with the HH group exhibiting the lowest survival rate. Baseline characteristics, including age, disease duration, MG severity scores, BMD, and FRAX® scores, differed significantly among groups. Specific MG-ADL items reflecting greater impairment (impairment of ability to arise from a chair, double vision, and ptosis) were significantly more pronounced in the HH group at baseline. Conclusions: Combining baseline FRAX® scores with the MG-ADL assessment effectively stratifies long-term MOF risk in patients with MG. Individuals with both high FRAX® and high MG-ADL represent a particularly high-risk subgroup. This dual-assessment approach may improve the identification of patients requiring targeted preventive interventions.
期刊介绍:
Journal of Clinical Medicine (ISSN 2077-0383), is an international scientific open access journal, providing a platform for advances in health care/clinical practices, the study of direct observation of patients and general medical research. This multi-disciplinary journal is aimed at a wide audience of medical researchers and healthcare professionals.
Unique features of this journal:
manuscripts regarding original research and ideas will be particularly welcomed.JCM also accepts reviews, communications, and short notes.
There is no limit to publication length: our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible.